Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Steering anti-cancer drugs away from the TRAIL

Nature Medicine volume 6, pages 502–503 (2000)Cite this article

TRAIL, a cytokine of the TNF family, has been hyped as an almost ‘magical’ drug for cancer treatment. However, its possible side effects in the liver raise serious concerns about its likelihood for development into a safe therapeutic product (pages 564–567 ).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Old, L.J. Tumor necrosis factor (TNF). Science 230, 630–632 (1985).

    Article  CAS  Google Scholar 

  2. Vassalli, P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411–452 ( 1992).

    Article  CAS  Google Scholar 

  3. Trauth, B.C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301– 305 (1989).

    Article  CAS  Google Scholar 

  4. Ogasawara, J. et al. Lethal effect of the anti-Fas antibody in mice. Nature 364, 806–809 ( 1993).

    Article  CAS  Google Scholar 

  5. Willey, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).

    Article  Google Scholar 

  6. Pitti, R.M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687–12690 (1996).

    Article  CAS  Google Scholar 

  7. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157 –163 (1999).

    Article  CAS  Google Scholar 

  8. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155– 162 (1999).

    Article  CAS  Google Scholar 

  9. Jo, M. et al. TNF-related apoptosis inducing ligand (TRAIL)-induced apoptosis in normal human hepatocytes. Nature Med. 6, 564–567 (2000)

    Article  CAS  Google Scholar 

  10. Nagata, S. Apoptosis by death factor. Cell 88, 355– 365 (1997).

    Article  CAS  Google Scholar 

  11. Ashkenazi, A. & Dixit, V.M. Death receptors: signaling and modulation . Science 281, 1305–1308 (1998).

    Article  CAS  Google Scholar 

  12. Nagata, S. Fas ligand-induced apoptosis. Annu. Rev. Genetics 33 , 29–55 (1999).

    Article  CAS  Google Scholar 

  13. Bodmer, J.-L. et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8 . Nature Cell Biol. 2, 241– 243 (2000).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics, Osaka University Medical School and Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan

    Shigekazu Nagata

Authors
  1. Shigekazu Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagata, S. Steering anti-cancer drugs away from the TRAIL. Nat Med 6, 502–503 (2000). https://doi.org/10.1038/74972

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/74972

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing